Cell-free DNA Testing Market – Global Drivers, Restraints, Opportunities, Trends, and Forecasts: 2017–2023
Cell-free DNA Testing Market – Global Drivers, Restraints, Opportunities, Trends, and Forecasts: 2017–2023
Overview: Cell-free DNA (cfDNA) are non-encapsulated fragments of DNA molecule present in blood and urine that has huge screening and diagnostic applications. CfDNA is used for fetal DNA screening tests to detect chromosomal abnormalities, as a biomarker for specific mutations detection in cancer patients, as a biomarker to detect post transplantation rejection, and other applications. According to the Center of Disease Control and Prevention, around 6,000 babies are born with Down syndrome every year that is nearly 1 in every 700 babies and the disease incidence is increased by about 30% between 1979 and 2003. Further, according to the study by World Health Organization, approximately 14 million new cancer cases were diagnosed and is expected to grow by about 70% over the next 2 decades.
The cfDNA testing market is booming due to advanced maternal age, increasing number of chronic diseases, change in lifestyle that leads to lifestyle diseases like cancer, and unhealthy food habits. The rising disease incidence along with the increasing medical spending and healthcare expenditure provide opportunities for molecular diagnostics company to come up with more number of innovative tests in the market. However, there is a huge market space for molecular diagnostic companies to come up with novel tests directing on transplantation rejection cases like liver, lung, etc, in the near future.
Market Analysis: The “Global Cell-free DNA Testing Market” is estimated to witness a CAGR of 26.5% during the forecast period 2017–2023. The market is analyzed based on three segments, namely test types, application, and regions.
Regional Analysis: The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (RoW). The Americas is set to be the leading region for the cfDNA testing market growth followed by Europe. Asia Pacific and RoW are set to be the emerging regions.
Test Types Analysis: The global cfDNA testing market by test type is segmented into cell-free fetal DNA tests (also called NIPT), circulating tumor DNA tests, and donor-derived cell-free DNA tests. Cell-free fetal DNA tests is the largest segment, as women are more career-oriented, and the trend is seen in western countries to start family at a late age. These lead to an increase in the average maternal age. Donor-derived cfDNA tests are the fastest growing segment. The rising number of organ donors, increasing transplantation procedures, increasing healthcare awareness have made them the fastest growing segment of the market. The market is also witnessing various acquisitions, agreements, and new product launches and collaborations among the top players, which is defining the future of the global cfDNA testing market.
Application Analysis: The global cfDNA testing market by application is segmented into Gynecology, Oncology, and Transplantation. Gynecology occupies the largest market share and transplantation is expected to be the fastest growing segment during the forecasted period.
Key Players: Natera, Inc., Beijing Genomics Institute, F. Hoffmann-La Roche (Roche), Laboratory Corporation of America Holdings, Illumina, Inc., Guardant Health, Trovagene, Inc., Biocept, Inc., and other predominate & niche players.
Competitive Analysis: Currently, the cfDNA tests dominate the global cfDNA testing market. A lot of new players are focusing on this market to provide innovative tests with high accuracy and less turnaround time. Many major players in the market are launching new products to maintain their leadership in the market. Apart from this, the big players are acquiring small companies in the market to enhance their product portfolio and maintain their market leadership. For instance, in September 2016, LabCorp acquired Sequenom to strengthen its non-invasive prenatal testing product portfolio.
Benefits: The report provides complete details about the usage and adoption rate of cfDNA tests in various applications and regions. With that, the key stakeholders can know about the major trends, drivers, investments, vertical player’s initiatives, government initiatives toward the test adoption in the upcoming years along with the details of commercial tests available in the market. Moreover, the report provides details about the major challenges that are going to impact the market growth. Additionally, the report gives complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.
Key Stakeholders:
Overview: Cell-free DNA (cfDNA) are non-encapsulated fragments of DNA molecule present in blood and urine that has huge screening and diagnostic applications. CfDNA is used for fetal DNA screening tests to detect chromosomal abnormalities, as a biomarker for specific mutations detection in cancer patients, as a biomarker to detect post transplantation rejection, and other applications. According to the Center of Disease Control and Prevention, around 6,000 babies are born with Down syndrome every year that is nearly 1 in every 700 babies and the disease incidence is increased by about 30% between 1979 and 2003. Further, according to the study by World Health Organization, approximately 14 million new cancer cases were diagnosed and is expected to grow by about 70% over the next 2 decades.
The cfDNA testing market is booming due to advanced maternal age, increasing number of chronic diseases, change in lifestyle that leads to lifestyle diseases like cancer, and unhealthy food habits. The rising disease incidence along with the increasing medical spending and healthcare expenditure provide opportunities for molecular diagnostics company to come up with more number of innovative tests in the market. However, there is a huge market space for molecular diagnostic companies to come up with novel tests directing on transplantation rejection cases like liver, lung, etc, in the near future.
Market Analysis: The “Global Cell-free DNA Testing Market” is estimated to witness a CAGR of 26.5% during the forecast period 2017–2023. The market is analyzed based on three segments, namely test types, application, and regions.
Regional Analysis: The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (RoW). The Americas is set to be the leading region for the cfDNA testing market growth followed by Europe. Asia Pacific and RoW are set to be the emerging regions.
Test Types Analysis: The global cfDNA testing market by test type is segmented into cell-free fetal DNA tests (also called NIPT), circulating tumor DNA tests, and donor-derived cell-free DNA tests. Cell-free fetal DNA tests is the largest segment, as women are more career-oriented, and the trend is seen in western countries to start family at a late age. These lead to an increase in the average maternal age. Donor-derived cfDNA tests are the fastest growing segment. The rising number of organ donors, increasing transplantation procedures, increasing healthcare awareness have made them the fastest growing segment of the market. The market is also witnessing various acquisitions, agreements, and new product launches and collaborations among the top players, which is defining the future of the global cfDNA testing market.
Application Analysis: The global cfDNA testing market by application is segmented into Gynecology, Oncology, and Transplantation. Gynecology occupies the largest market share and transplantation is expected to be the fastest growing segment during the forecasted period.
Key Players: Natera, Inc., Beijing Genomics Institute, F. Hoffmann-La Roche (Roche), Laboratory Corporation of America Holdings, Illumina, Inc., Guardant Health, Trovagene, Inc., Biocept, Inc., and other predominate & niche players.
Competitive Analysis: Currently, the cfDNA tests dominate the global cfDNA testing market. A lot of new players are focusing on this market to provide innovative tests with high accuracy and less turnaround time. Many major players in the market are launching new products to maintain their leadership in the market. Apart from this, the big players are acquiring small companies in the market to enhance their product portfolio and maintain their market leadership. For instance, in September 2016, LabCorp acquired Sequenom to strengthen its non-invasive prenatal testing product portfolio.
Benefits: The report provides complete details about the usage and adoption rate of cfDNA tests in various applications and regions. With that, the key stakeholders can know about the major trends, drivers, investments, vertical player’s initiatives, government initiatives toward the test adoption in the upcoming years along with the details of commercial tests available in the market. Moreover, the report provides details about the major challenges that are going to impact the market growth. Additionally, the report gives complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.
Key Stakeholders:
1 INDUSTRY OUTLOOK
1.1 Industry overview
1.2 Total addressable market
1.3 Industry Trends
2 REPORT OUTLINE
2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions
3 MARKET SNAPSHOT
3.1 Market Definition – Infoholic Research
3.2 Importance of Cell-Free DNA testing
3.3 Complications of Cell-Free DNA testing
3.4 Segmented Addressable Market (SAM)
3.5 Industry Trends
3.6 Related Markets
3.6.1 Liquid biopsy market
3.6.2 Transplantation Diagnostics Market
4 MARKET OUTLOOK
4.1 Overview
4.2 Regulatory framework
4.3 Funding scenario
4.4 Market segmentation
4.5 PEST Analysis
4.6 Porter 5(Five) Forces
5 MARKET CHARACTERISTICS
5.1 DRO – Global Cell-free DNA testing Market Dynamics
5.1.1 Drivers
5.1.1.1 Rising incidence of babies with chromosomal disorders due to increasing number of late pregnancies
5.1.1.2 Rising number of cancers
5.1.1.3 Growing demand through non-invasive procedures for early disease diagnosis
5.1.2 Opportunities
5.1.2.1 Increase healthcare spending and growing healthcare awareness in emerging countries
5.1.2.2 Increase in mergers & acquisitions
5.1.3 Restraints
5.1.3.1 High test cost with less reimbursement facilities
5.1.3.2 Ethical issues
5.1.3.3 Lack of skilled professionals for performing advanced diagnostic testing
6 TEST TYPES: MARKET SIZE AND ANALYSIS
6.1 Overview
6.2 Non-invasive prenatal testing (NIPT)
6.3 Circulating tumour DNA tests
6.4 Donor-derived cell free DNA tests
7 APPLICATION: MARKET SIZE AND ANALYSIS
7.1 Overview
7.2 Prenatal testing
7.3 Cancer
7.4 Transplantation diagnostics
8 REGIONS: MARKET SIZE AND ANALYSIS
8.1 Overview
8.2 North America
8.2.1 Overview
8.2.2 United states
8.2.3 Canada
8.3 Europe
8.3.1 Overview
8.3.2 United Kingdom
8.3.3 Germany
8.3.4 France
8.3.5 Spain
8.4 APAC
8.4.1 Overview
8.4.2 India
8.4.3 China
8.5 Rest of the World
8.5.1 Overview
8.5.2 Brazil
8.5.3 Middle East
9 COMPETITIVE LANDSCAPE
9.1 Overview
10 VENDOR PROFILES
10.1 Natera, Inc.
10.1.1 Overview
10.1.2 Natera Inc.:Product offerings
10.1.3 NATERA, INC.: Recent Developments
10.1.4 Geographic Presence
10.1.5 Business Focus
10.1.6 SWOT Analysis
10.1.7 Business Strategy
10.2 Laboratory Corporation of America Holdings (LABCORP)
10.2.1 Overview
10.2.2 Laboratory Corporaton Of America Holdings: Product Offerings
10.2.3 Laboratory Corporation Of America Holdings: Recent Developments
10.2.4 Business Unit
10.2.5 Geographic Presence
10.2.6 Business Focus
10.2.7 SWOT Analysis
10.2.8 Business Strategy
10.3 Illumina, Inc.,
10.3.1 Overview
10.3.2 Illumina, INC: Product offerings
10.3.3 Illumina, INC: Recent Developments
10.3.4 Geographic Presence
10.3.5 Business Focus
10.3.6 SWOT Analysis
10.3.7 Business Strategy
10.4 BEIJING GENOMICS INSTITUTE
10.4.1 Overview
10.4.2 Beijing Genomics Institute: Product offerings
10.4.3 Beijing Genomics Institute: Recent Developments
10.4.4 Business Focus
10.4.5 SWOT Analysis
10.4.6 Business Strategy
10.5 F.Hoffmann-La Roche Ltd
10.5.1 Overview
10.5.2 F. Hoffmann-la Roche: Product Offerings
10.5.3 F. Hoffmann-la roche.: Recent Developments
10.5.4 Business Unit
10.5.5 Geographic Presence
10.5.6 Business Focus
10.5.7 SWOT Analysis
10.5.8 Business Strategy
Companies to Watch For
10.6 CareDx, Inc
10.6.1 Overview
10.6.2 caredx: Recent Developments
10.7 LifeCodexx AG
10.7.1 Overview
10.7.2 LifeCodexx AG: Recent Developments
10.8 Biocept, Inc.
10.8.1 Overview
10.8.2 Biocept, Inc.: Recent Developments
10.9 Quest Diagnostics
10.9.1 Overview
10.9.2 Quest Diagnostics: Recent Developments
10.10 Guardant Health
10.10.1 Overview
10.10.2 Guardant Health: Recent Developments
10.11 Inivata Limited
10.11.1 Overview
10.11.2 Inivata Limited: Recent Developments
10.12 Personal Genome Diagnostics
10.12.1 Overview
10.12.2 Personal Genome Diagnostics: Recent Developments
10.13 Trovagene
10.13.1 Overview
10.13.2 Trovagene, Inc.: Recent Developments
Annexure
Abbreviations
Tables
Table 1 FUNDING SCENARIO
Table 2 GLOBAL CELL-FREE DNA TESTING MARKET BY TEST TYPES, 2016–2023 ($MILLION)
Table 3 GLOBAL CELL-FREE DNA TESTING MARKET BY APPLICATION, 2016–2023 ($MILLION)
Table 4 GLOBAL CELL-FREE DNA TESTING MARKET REVENUE BY REGIONS, 2016–2023 ($MILLION)
Table 5 GLOBAL NON-INVASIVE PRENATAL TESTING MARKET BY VENDOR RANKING, 2016
Table 6 OTHER PROMINENT VENDORS OF CELL-FREE DNA TESTING MARKET
Table 7 CAREDX, INC.: SNAPSHOT
Table 8 LIFECODEXX AG.: SNAPSHOT
Table 9 BIOCEPT, INC.: SNAPSHOT
Table 10 QUEST DIAGNOSTICS: SNAPSHOT
Table 11 GUARDANT HEALTH INC.: SNAPSHOT
Table 12 INIVATA LIMITED: SNAPSHOT
Table 13 PERSONAL GENOME DIAGNOSTICS: SNAPSHOT
Table 14 TROVAGENE, INC.: SNAPSHOT
Charts
Chart 1 RESEARCH METHODOLOGY OF GLOBAL CELL-FREE DNA TESTING MARKET
Chart 2 WORLDWIDE CELL-FREE DNA TESTING MARKET REVENUE, 2016–2023 ($MILLION)
Chart 3 PEST ANALYSIS OF GLOBAL CELL-FREE DNA TESTING MARKET
Chart 4 PORTER 5 FORCES ON GLOBAL CELL-FREE DNA TESTING MARKET
Chart 5 DRO – IMPACT ANALYSIS OF GLOBAL CELL-FREE DNA TESTING MARKET
Chart 6 KEY STAKEHOLDERS
Chart 7 GLOBAL CELL-FREE DNA TESTING MARKET BY TEST TYPE SEGMENTATION, 2016 (%)
Chart 8 GLOBAL CELL-FREE DNA TESTING MARKET BY TEST TYPE SEGMENTATION, 2023 (%)
Chart 9 GLOBAL NON-INVASIVE PRENATAL TESTING MARKET REVENUE FORECAST,
2016–2023 ($MILLION)
Chart 10 GLOBAL CIRCULATING TUMOUR DNA MARKET REVENUE FORECAST, 2016–2023 ($MILLION)
Chart 11 GLOBAL DONOR-DERIVED CELL-FREE DNA TESTING MARKET REVENUE FORECAST, 2016–2023 ($MILLION)
Chart 12 GLOBAL CELL-FREE DNA TESTING MARKET BY APPLICATION SEGMENTATION, 2016 (%)
Chart 13 GLOBAL CELL-FREE DNA TESTING MARKET BY APPLICATION SEGMENTATION, 2023 (%)
Chart 14 GLOBAL CELL-FREE DNA TESTING MARKET BY GEOGRAPHICAL SEGMENTATION, 2016 (%)
Chart 15 CELL-FREE DNA TESTING MARKET REVENUE IN NORTH AMERICA, 2016–2023 ($MILLION)
Chart 16 CELL-FREE DNA TESTING MARKET REVENUE IN EUROPE, 2016–2023 ($MILLION)
Chart 17 CELL-FREE DNA TESTING MARKET REVENUE IN ASIA-PACIFIC, 2016–2023 ($MILLION)
Chart 18 CELL-FREE DNA TESTING MARKET REVENUE IN REST OF THE WORLD, 2016–2023 ($MILLION)
Chart 19 NATERA: OVERVIEW SNAPSHOT
Chart 20 NATERA: GEOGRAPHIC PRESENCE
Chart 21 NATERA: SWOT ANALYSIS
Chart 22 LABORATORY CORPORATION OF AMERICA HOLDINGS: OVERVIEW SNAPSHOT
Chart 23 LABORATORY CORPORATION OF AMERICA HOLDINGS: BUSINESS UNITS
Chart 24 LABORATORY CORPORTATION OF AMERICA HOLDINGS: GEOGRAPHICAL PRESENCE
Chart 25 LABORATORY CORPORATION OF AMERICA HOLDINGS: SWOT ANALYSIS
Chart 26 ILLUMINA, INC: OVERVIEW SNAPSHOT
Chart 27 ILLUMINA, INC: GEOGRAPHIC PRESENCE
Chart 28 ILLUMINA, INC: SWOT ANALYSIS
Chart 29 BEIJING GENOMICS INSTITUTE: SWOT ANALYSIS
Chart 30 F. HOFFMANN-LA ROCHE: OVERVIEW SNAPSHOT
Chart 31 F. HOFFMANN.LA ROCHE: BUSINESS UNITS
Chart 32 F. HOFFMANN-LA ROCHE: GEOGRAPHICAL PRESENCE
Chart 33 F. HOFFMANN-LA ROCHE: SWOT ANALYSIS
1.1 Industry overview
1.2 Total addressable market
1.3 Industry Trends
2 REPORT OUTLINE
2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions
3 MARKET SNAPSHOT
3.1 Market Definition – Infoholic Research
3.2 Importance of Cell-Free DNA testing
3.3 Complications of Cell-Free DNA testing
3.4 Segmented Addressable Market (SAM)
3.5 Industry Trends
3.6 Related Markets
3.6.1 Liquid biopsy market
3.6.2 Transplantation Diagnostics Market
4 MARKET OUTLOOK
4.1 Overview
4.2 Regulatory framework
4.3 Funding scenario
4.4 Market segmentation
4.5 PEST Analysis
4.6 Porter 5(Five) Forces
5 MARKET CHARACTERISTICS
5.1 DRO – Global Cell-free DNA testing Market Dynamics
5.1.1 Drivers
5.1.1.1 Rising incidence of babies with chromosomal disorders due to increasing number of late pregnancies
5.1.1.2 Rising number of cancers
5.1.1.3 Growing demand through non-invasive procedures for early disease diagnosis
5.1.2 Opportunities
5.1.2.1 Increase healthcare spending and growing healthcare awareness in emerging countries
5.1.2.2 Increase in mergers & acquisitions
5.1.3 Restraints
5.1.3.1 High test cost with less reimbursement facilities
5.1.3.2 Ethical issues
5.1.3.3 Lack of skilled professionals for performing advanced diagnostic testing
6 TEST TYPES: MARKET SIZE AND ANALYSIS
6.1 Overview
6.2 Non-invasive prenatal testing (NIPT)
6.3 Circulating tumour DNA tests
6.4 Donor-derived cell free DNA tests
7 APPLICATION: MARKET SIZE AND ANALYSIS
7.1 Overview
7.2 Prenatal testing
7.3 Cancer
7.4 Transplantation diagnostics
8 REGIONS: MARKET SIZE AND ANALYSIS
8.1 Overview
8.2 North America
8.2.1 Overview
8.2.2 United states
8.2.3 Canada
8.3 Europe
8.3.1 Overview
8.3.2 United Kingdom
8.3.3 Germany
8.3.4 France
8.3.5 Spain
8.4 APAC
8.4.1 Overview
8.4.2 India
8.4.3 China
8.5 Rest of the World
8.5.1 Overview
8.5.2 Brazil
8.5.3 Middle East
9 COMPETITIVE LANDSCAPE
9.1 Overview
10 VENDOR PROFILES
10.1 Natera, Inc.
10.1.1 Overview
10.1.2 Natera Inc.:Product offerings
10.1.3 NATERA, INC.: Recent Developments
10.1.4 Geographic Presence
10.1.5 Business Focus
10.1.6 SWOT Analysis
10.1.7 Business Strategy
10.2 Laboratory Corporation of America Holdings (LABCORP)
10.2.1 Overview
10.2.2 Laboratory Corporaton Of America Holdings: Product Offerings
10.2.3 Laboratory Corporation Of America Holdings: Recent Developments
10.2.4 Business Unit
10.2.5 Geographic Presence
10.2.6 Business Focus
10.2.7 SWOT Analysis
10.2.8 Business Strategy
10.3 Illumina, Inc.,
10.3.1 Overview
10.3.2 Illumina, INC: Product offerings
10.3.3 Illumina, INC: Recent Developments
10.3.4 Geographic Presence
10.3.5 Business Focus
10.3.6 SWOT Analysis
10.3.7 Business Strategy
10.4 BEIJING GENOMICS INSTITUTE
10.4.1 Overview
10.4.2 Beijing Genomics Institute: Product offerings
10.4.3 Beijing Genomics Institute: Recent Developments
10.4.4 Business Focus
10.4.5 SWOT Analysis
10.4.6 Business Strategy
10.5 F.Hoffmann-La Roche Ltd
10.5.1 Overview
10.5.2 F. Hoffmann-la Roche: Product Offerings
10.5.3 F. Hoffmann-la roche.: Recent Developments
10.5.4 Business Unit
10.5.5 Geographic Presence
10.5.6 Business Focus
10.5.7 SWOT Analysis
10.5.8 Business Strategy
Companies to Watch For
10.6 CareDx, Inc
10.6.1 Overview
10.6.2 caredx: Recent Developments
10.7 LifeCodexx AG
10.7.1 Overview
10.7.2 LifeCodexx AG: Recent Developments
10.8 Biocept, Inc.
10.8.1 Overview
10.8.2 Biocept, Inc.: Recent Developments
10.9 Quest Diagnostics
10.9.1 Overview
10.9.2 Quest Diagnostics: Recent Developments
10.10 Guardant Health
10.10.1 Overview
10.10.2 Guardant Health: Recent Developments
10.11 Inivata Limited
10.11.1 Overview
10.11.2 Inivata Limited: Recent Developments
10.12 Personal Genome Diagnostics
10.12.1 Overview
10.12.2 Personal Genome Diagnostics: Recent Developments
10.13 Trovagene
10.13.1 Overview
10.13.2 Trovagene, Inc.: Recent Developments
Annexure
Abbreviations
Tables
Table 1 FUNDING SCENARIO
Table 2 GLOBAL CELL-FREE DNA TESTING MARKET BY TEST TYPES, 2016–2023 ($MILLION)
Table 3 GLOBAL CELL-FREE DNA TESTING MARKET BY APPLICATION, 2016–2023 ($MILLION)
Table 4 GLOBAL CELL-FREE DNA TESTING MARKET REVENUE BY REGIONS, 2016–2023 ($MILLION)
Table 5 GLOBAL NON-INVASIVE PRENATAL TESTING MARKET BY VENDOR RANKING, 2016
Table 6 OTHER PROMINENT VENDORS OF CELL-FREE DNA TESTING MARKET
Table 7 CAREDX, INC.: SNAPSHOT
Table 8 LIFECODEXX AG.: SNAPSHOT
Table 9 BIOCEPT, INC.: SNAPSHOT
Table 10 QUEST DIAGNOSTICS: SNAPSHOT
Table 11 GUARDANT HEALTH INC.: SNAPSHOT
Table 12 INIVATA LIMITED: SNAPSHOT
Table 13 PERSONAL GENOME DIAGNOSTICS: SNAPSHOT
Table 14 TROVAGENE, INC.: SNAPSHOT
Charts
Chart 1 RESEARCH METHODOLOGY OF GLOBAL CELL-FREE DNA TESTING MARKET
Chart 2 WORLDWIDE CELL-FREE DNA TESTING MARKET REVENUE, 2016–2023 ($MILLION)
Chart 3 PEST ANALYSIS OF GLOBAL CELL-FREE DNA TESTING MARKET
Chart 4 PORTER 5 FORCES ON GLOBAL CELL-FREE DNA TESTING MARKET
Chart 5 DRO – IMPACT ANALYSIS OF GLOBAL CELL-FREE DNA TESTING MARKET
Chart 6 KEY STAKEHOLDERS
Chart 7 GLOBAL CELL-FREE DNA TESTING MARKET BY TEST TYPE SEGMENTATION, 2016 (%)
Chart 8 GLOBAL CELL-FREE DNA TESTING MARKET BY TEST TYPE SEGMENTATION, 2023 (%)
Chart 9 GLOBAL NON-INVASIVE PRENATAL TESTING MARKET REVENUE FORECAST,
2016–2023 ($MILLION)
Chart 10 GLOBAL CIRCULATING TUMOUR DNA MARKET REVENUE FORECAST, 2016–2023 ($MILLION)
Chart 11 GLOBAL DONOR-DERIVED CELL-FREE DNA TESTING MARKET REVENUE FORECAST, 2016–2023 ($MILLION)
Chart 12 GLOBAL CELL-FREE DNA TESTING MARKET BY APPLICATION SEGMENTATION, 2016 (%)
Chart 13 GLOBAL CELL-FREE DNA TESTING MARKET BY APPLICATION SEGMENTATION, 2023 (%)
Chart 14 GLOBAL CELL-FREE DNA TESTING MARKET BY GEOGRAPHICAL SEGMENTATION, 2016 (%)
Chart 15 CELL-FREE DNA TESTING MARKET REVENUE IN NORTH AMERICA, 2016–2023 ($MILLION)
Chart 16 CELL-FREE DNA TESTING MARKET REVENUE IN EUROPE, 2016–2023 ($MILLION)
Chart 17 CELL-FREE DNA TESTING MARKET REVENUE IN ASIA-PACIFIC, 2016–2023 ($MILLION)
Chart 18 CELL-FREE DNA TESTING MARKET REVENUE IN REST OF THE WORLD, 2016–2023 ($MILLION)
Chart 19 NATERA: OVERVIEW SNAPSHOT
Chart 20 NATERA: GEOGRAPHIC PRESENCE
Chart 21 NATERA: SWOT ANALYSIS
Chart 22 LABORATORY CORPORATION OF AMERICA HOLDINGS: OVERVIEW SNAPSHOT
Chart 23 LABORATORY CORPORATION OF AMERICA HOLDINGS: BUSINESS UNITS
Chart 24 LABORATORY CORPORTATION OF AMERICA HOLDINGS: GEOGRAPHICAL PRESENCE
Chart 25 LABORATORY CORPORATION OF AMERICA HOLDINGS: SWOT ANALYSIS
Chart 26 ILLUMINA, INC: OVERVIEW SNAPSHOT
Chart 27 ILLUMINA, INC: GEOGRAPHIC PRESENCE
Chart 28 ILLUMINA, INC: SWOT ANALYSIS
Chart 29 BEIJING GENOMICS INSTITUTE: SWOT ANALYSIS
Chart 30 F. HOFFMANN-LA ROCHE: OVERVIEW SNAPSHOT
Chart 31 F. HOFFMANN.LA ROCHE: BUSINESS UNITS
Chart 32 F. HOFFMANN-LA ROCHE: GEOGRAPHICAL PRESENCE
Chart 33 F. HOFFMANN-LA ROCHE: SWOT ANALYSIS
